Dapagliflozin (BMS-512148)

For research use only.

Catalog No.S1548

23 publications

Dapagliflozin (BMS-512148) Chemical Structure

CAS No. 461432-26-8

Dapagliflozin (BMS-512148) is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 4.

Selleck's Dapagliflozin (BMS-512148) has been cited by 23 publications

Purity & Quality Control

Choose Selective SGLT Inhibitors

Biological Activity

Description Dapagliflozin (BMS-512148) is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 4.
Features More potent stimulator of glucosuria than other SGLT2 inhibitors.
Targets
hSGLT2 [1]
(CHO cells)
1.1 nM(EC50)
In vitro

Dapagliflozin is not sensitive to hSGLT1 with a 1200-fold IC50. [1] Dapagliflozin is 32-fold more potent than phlorizin against hSGLT2 but 4-fold less than phlorizin against hSGLT1. Dapagliflozin is highly selective versus GLUT transporters and displays 8–9% inhibition in protein-free buffer at 20 μM and virtually no inhibition in the presence of 4% bovine serum albumin. [2] Dapagliflozin has good permeability across Caco-2 cell membranes and is a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin is stable in rat, dog, monkey, and human serum at 10 μM. Dapagliflozin shows no inhibitory responses or induction to human P450 enzymes. The in vitro metabolic pathways Dapagliflozin are glucuronidation, hydroxylation, and O-deethylation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells MXfGeY5kfGmxbjDhd5NigQ>? MlzpNkBp MnyyTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IGuxOGNe[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMES5JO69VQ>? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR|NEmwPUc,OjB2M{S5NFk9N2F-
CHOK1 cells Ml3PSpVv[3Srb36gZZN{[Xl? NU\ISHF4OyCq NVnvXmRSUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPT|Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbNVREZS2DTVegeZB1[WunIHHmeIVzKDNiaILzJIJ6KG2rY4LvZoV1[SC|Y3nueIltdGG2aX;uJINwfW62aX7nJIFv[Wy7c3nzMEBKSzVyPUCuNFAyKM7:TR?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh2Mk[xPEc,OjR6NEK2NVg9N2F-
HEK293.ETN cells M{\3NmZ2dmO2aX;uJIF{e2G7 MYOxMlUhcA>? MojiTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjD0doFve2[nY4Tl[EBqdiCKRVuyPVMvTVSQIHPlcIx{KGG|c3Xzd4VlKGG|IFHNS{B2eHSja3WgZYZ1\XJiMT61JIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvODB4NzFOwG0> NFzJV3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi5OlM4PCd-MUm4PVY{PzR:L3G+
COS-7 cells M3Po[mZ2dmO2aX;uJIF{e2G7 NIjHdHIzKGh? MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIITyZY5{\mWldHXkJIlvKEORUz23JINmdGy|IHHzd4V{e2WmIHHzJGFOTyC3cIThb4Uh[W[2ZYKgNkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjh7IN88US=> M2\CSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm2N|c1Lz5zOUi5OlM4PDxxYU6=
CHO MW\GeY5kfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcOTSFXVHNS{Bi[2O3bYXsZZRqd25uIFXDOVAhRSByLkCwNVEh|ryPLh?= NG\aTnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK2NFYyQCd-MUiyOlA3OTh:L3G+
CHO M2m0[mZ2dmO2aX;uJIF{e2G7 MYDJcohq[mm2aX;uJI9nKHKjdDDTS2xVOiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|E1S12DTVegZYNkfW23bHH0bY9vNCCHQ{WwJF0hOC5yMEOg{txONg>? NHntPGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK2NFYyQCd-MUiyOlA3OTh:L3G+
CHO MoDTSpVv[3Srb36gZZN{[Xl? NILlfFJKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYWFOTyCjY3P1cZVt[XSrb36sJGVEPTBiPTCxMlM6KM7:TT6= NWLTO5VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOlA3OThpPkG4NlYxPjF6PD;hQi=>
HEK293.ETN MlexSpVv[3Srb36gZZN{[Xl? NH[wR3RKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCKRVuyPVMvTVSQIHPlcIx{KGG|c3Xzd4VlKGG|IH3leIh6dC2jbIDoZU1FNVuXLUG0R31odHWlb4D5doFvd3OrZHWgeZB1[WunIHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkCwOlch|ryPLh?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdyMEOxPEc,OTl5MECzNVg9N2F-
COS7 NIf5[IlHfW6ldHnvckBie3OjeR?= M3LGTGlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgZZN{\XO|ZXSgZZMhdWW2aInsMYFteGijLVStX3UuOTSFXXfseYNweHm{YX7vd4ll\SC3cIThb4Uh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvQDh3IN88UU4> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdyMEOxPEc,OTl5MECzNVg9N2F-
HEK293 NXPUelRxTnWwY4Tpc44h[XO|YYm= NWT4cHZ6UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|E1S12jbIDoZU1u\XSqeXzncJVkd3C7cnHuc5Nq\GVidYD0ZYtmNCCLQ{WwJF0hOC56MTFOwG0v MoWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEW0N|UoRjF7N{i1OFM2RC:jPh?=
CHO NUP2bWVuTnWwY4Tpc44h[XO|YYm= M1Oz[FIhcHK| NV3MVJNZUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zic3;kbZVuNWSncHXu[IVvfCCvZYTofYwu[WyyaHGtSE1cXS1zNFPd[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czygTWM2OCB;IECuNFAyPCEQvF2u NFTXeY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY2Oyd-MkCxOFk3PTN:L3G+
CHO NHrBNndHfW6ldHnvckBie3OjeR?= MX[yJIhzew>? NXzIR|A2UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zic3;kbZVuNWSncHXu[IVvfCCvZYTofYwu[WyyaHGtSE1cXS1zNFPd[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czygTWM2OCB;IEGuNkDPxE1w NFXOV449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY2Oyd-MkCxOFk3PTN:L3G+
CHO M2jvbmZ2dmO2aX;uJIF{e2G7 NWqybY5uUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDTS2xVOiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6wNFA1QSEQvF2u NV;KfG5QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxPFE1QDZpPkKwNVgyPDh4PD;hQi=>
HEK293 NVfs[|l7TnWwY4Tpc44h[XO|YYm= M1LNfVEvPSCqcoO= M17RcGlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuxOGNe[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAyNjViaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6wNFY4KM7:TT6= NHToeZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW3OlU4QCd-MkC1O|Y2Pzh:L3G+
COS7 MnnvSpVv[3Srb36gZZN{[Xl? MXeyJIhzew>? M2\1W2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbNVREZWGucHjhMY1mfGi7bD3EMYdtfWOxcInyZY5we2mmZTD1dJRic2ViYX\0[ZIhOiCqcoOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLki5JO69VS5? MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3N{[1O|goRjJyNUe2OVc5RC:jPh?=
CHO NF;ObWRHfW6ldHnvckBie3OjeR?= MWGyJIhzew>? M1rWOmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDzc4RqfW1vZHXw[Y5l\W62IGuxOGNeNWGucHjhMY1mfGi7bD3EMYdtfWOxcInyZY5we2mmZTD1dJRic2ViYX\0[ZIhOiCqcoOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFXDOVAhRSByLkCwN{DPxE1w M{[wfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUK4OVkzLz5{MUGyPFU6OjxxYU6=
CHO NYmwU20{TnWwY4Tpc44h[XO|YYm= NIfMWXIzKGi{cx?= NVTHUGhqUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJJNw\Gm3bT3k[ZBmdmSnboSgX|E1S11vYXzwbIEudWW2aInsMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygSWM2OCB;IECuOFI5PSEQvF2u M4WwXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUK4OVkzLz5{MUGyPFU6OjxxYU6=
CHO M{jqUWZ2dmO2aX;uJIF{e2G7 M1rZTVIhcHK| NHfuSGJKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYYFteGijLX3leIh6dC2GLXfseYNweHm{YX7vd4ll\SC3cIThb4Uh[W[2ZYKgNkBpenNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjByMES5JO69VS5? MkX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzOUOzNFgoRjJzMUmzN|A5RC:jPh?=
CHO MUXGeY5kfGmxbjDhd5NigQ>? NXz1Z3FwPjBibXnudy=> M1rnWmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFtzNFPdMYFteGijLX3leIh6dC2GLXfseYNweHm{YX7vd4ll\SC2cnHud5BwenRiYX\0[ZIhPjBibXnud{BjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gNE4xODRizszNMi=> NYPJZXJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPVgyOjRpPkKxN|k5OTJ2PD;hQi=>
CHO NY\QS|ViTnWwY4Tpc44h[XO|YYm= NHTSU4o3OCCvaX7z NF3HT|lKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYU1idHCqYT3t[ZRpgWxvRD3ncJVkd3C7cnHuc5Nq\GVidILhcpNxd3K2IHHmeIVzKDZyIH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{BqdiCycnXz[Y5k\SCxZjCxNFAmKHCuYYPtZUwhUUN3MDC9JFAvODJ{IN88UU4> NETEXok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO5PFEzPCd-MkGzPVgyOjR:L3G+
CHO NHrCTZFHfW6ldHnvckBie3OjeR?= MUG2NEBucW6| MWnJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcOTSFXT3hcJBp[S2vZYTofYwuTC2pbIXjc5B6emGwb4Pp[IUhfHKjboPwc5J1KGGodHXyJFYxKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuN|ch|ryPLh?= Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OUixNlQoRjJzM{m4NVI1RC:jPh?=
CHO NGjpfphHfW6ldHnvckBie3OjeR?= MVe2NEBucW6| MoP3TY5pcWKrdHnvckBw\iCVR1zUOkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R30u[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIITyZY5{eG:{dDDh[pRmeiB4MDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjN6IN88UU4> M4mzXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{m4NVI1Lz5{MUO5PFEzPDxxYU6=
CHO NFzjU4VHfW6ldHnvckBie3OjeR?= MmDJNkBpenN? NEXTSHdKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgX|E1S11vYXzwbIEudWW2aInsMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGW{LDDJR|UxKD1iMD6wNFA1QSEQvF2u MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzNECxOEc,OjF3MUSwNVQ9N2F-
CHO MWfGeY5kfGmxbjDhd5NigQ>? MonGOlAhdWmwcx?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcOTSFXT3HcJVkd3OnIIXweIFs\SC3c3nu[{BcOTSFXT3t[ZRpgWxiZ3z1Z49xgXKjbn;zbYRmKGGodHXyJFYxKG2rboOgZpkhdWmlcn;i[ZRiKHCuYYTlJINwfW62aX7nMEBKSzVyIE2gNE4xODNizszNMi=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV4NUS5O{c,OjF3NkW0PVc9N2F-
CHO NHPGXHpHfW6ldHnvckBie3OjeR?= NU\UeXNlUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IIXzbY5oKG2ndHj5cE1idHCqYT3EMYdtfWOxcInyZY5we2mmZTDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMECxN|Uh|ryPLh?= Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3OUK3PVQoRjJzNUmyO|k1RC:jPh?=
COS7 MWjGeY5kfGmxbjDhd5NigQ>? M2HxOlIhcHK| Ml2yTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuxOGNeNW2ndHj5cE1idHCqYT3EMYdtfWOxcInyZY5we2mmZTD1dJRic2ViYX\0[ZIhOiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDpckBxemW|ZX7j[UBw\iB{NTClJIh2dWGwIIDsZZNu[SxiSVO1NEA:KDBwMECzNkDPxE1w MlvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{eyOlYoRjJzN{O3NlY3RC:jPh?=
293 M2rZOWZ2dmO2aX;uJIF{e2G7 NUCwV45GOS53IHjydy=> MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBpfW2jbjCyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbNVREZS2vZYTofYwu[WyyaHGtSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDFwNTDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{BqdiCycnXz[Y5k\SCxZjCyOUAmKGi3bXHuJJBt[XOvYTygTWM2OCB;IEOuNUDPxE1w NXfEfXdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|czPjZpPkKxO|M4OjZ4PD;hQi=>
CHO MlrkSpVv[3Srb36gZZN{[Xl? MXyyJIhzew>? Ml\hTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBcOTSFXT3sZYJmdGWmIFHNS{Bi\nSncjCyJIhzeyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvODBzM{Wg{txONg>? M4PKO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOE[4NlM6Lz5{MUi2PFI{QTxxYU6=
CHO NXXhSoRCTnWwY4Tpc44h[XO|YYm= NGe4SXozKGi{cx?= NGLBS5FKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgX|E1S11vYXzwbIEudWW2aInsMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNFAxPDlizszNMi=> M3HwclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUC2PVU{Lz5{MUmwOlk2OzxxYU6=
CHO-K1 MXPGeY5kfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9vS{GgZ4VtdHNiYomgX|E1S12DTVegeZB1[WunIHHzd4F6NCCLQ{WwJF0hOC5yMEGzJO69VS5? M4TQU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkWyNlU2Lz5{Mk[1NlI2PTxxYU6=
CHO-K1 NXTiRpE6TnWwY4Tpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBEUE9vS{GgZ4VtdHNiYomgX|E1S12DTVegeZB1[WunIHHzd4F6NCCLQ{WwJF0hOC56IN88UU4> Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUKyOVUoRjJ{NkWyNlU2RC:jPh?=
CHO-K1 NIKxW3pHfW6ldHnvckBie3OjeR?= NVGycIJkOTJyIH3pcpM> M3jkT2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTz3LNUBk\WyuczDpcoN2[mG2ZXSg[o9zKDF{MDDtbY5{KGG2IEO3JIRm\0NiYomgX|E1S11vQV3HJJVxfGGtZTDhd5NigSxiRVO1NEA:KDBwMECyOEDPxE1w NUHDVYZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NVgxPDBpPkKyPFE5ODRyPD;hQi=>
CHO-K1 NWrIdWEzTnWwY4Tpc44h[XO|YYm= MYGxNlAhdWmwcx?= NFHYV5FKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgbY5kfWKjdHXkJIZweiBzMkCgcYlveyCjdDCzO{Bl\WeFIHL5JHsyPEOfLVHNS{B2eHSja3WgZZN{[XluIFXDOVAhRSByLkW5N{DPxE1w NEfHT4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkixPFA1OCd-MkK4NVgxPDB:L3G+
CHO NW\JOXlSTnWwY4Tpc44h[XO|YYm= MUe0OUBucW6| MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB{d2SrdX2t[IVx\W6mZX70JHsyPEOfbXX0bJltNWGucHjhMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB2NTDtbY5{NCCLQ{WwJF0hOC5yMEGzJO69VS5? NUD5U2xuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PFk{PTFpPkKyPFg6OzVzPD;hQi=>
CHO NH33bYJHfW6ldHnvckBie3OjeR?= MUi0OUBucW6| M2T3emlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHOxZHn1cU1l\XCnbnTlcpQhYzF2Q23t[ZRpgWxvYXzwbIEuTC2pbIXjc5B6emGwb4Pp[IUhfXC2YXvlJIFnfGW{IES1JI1qdnNuIFnDOVAhRSByLkig{txONg>? NXnsSG9QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PFk{PTFpPkKyPFg6OzVzPD;hQi=>
CHOK1 MUXGeY5kfGmxbjDhd5NigQ>? NFf6Rnk{KGi{cx?= MnToTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRS{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYU1CVUdidYD0ZYtmKGGodHXyJFMhcHK|IHL5JI1q[3KxYnX0ZUB{[2mwdHnscIF1cW:wIHPveY51cW6pIHHuZYx6e2m|LDDJR|UxKD1iMD64PVEh|ryPLh?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh2Mk[xPEc,OjR6NEK2NVg9N2F-
CHO MXnGeY5kfGmxbjDhd5NigQ>? NV\mR3JmOiCqcoO= MUDJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiW{G0R30u[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMECwOFkh|ryPLh?= NX;lWWNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzQTdpPkK0PVAxOjl5PD;hQi=>
CHO MXrGeY5kfGmxbjDhd5NigQ>? MmDaNkBpenN? NGTOZolEd22yZYTpeIl3\SCrbnjpZol1cW:wIH;mJIZ2dGxvbHXu[5RpKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB{d2SrdX2t[IVx\W6mZX70JHsyPEOfLXHsdIhiNW2ndHj5cE1FNWeudXPvdJlz[W6xc3nk[UB2eHSja3WgZYZ1\XJiMjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvODB3IN88UU4> Mkn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUCyOVQoRjJ3NkWwNlU1RC:jPh?=
CHO NYi4b3hPTnWwY4Tpc44h[XO|YYm= M4XjTlEzOCCvaX7z MY\Jcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6geZB1[WunIH;mJHsyPEOfQV3HJIFnfGW{IEGyNEBucW6|IHL5JHRweEOxdX70JI1mfGixZDygTWM2OCB;IECuNFAyPSEQvF2u M{Hrc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NES3O|kyLz5{OES0O|c6OTxxYU6=
CHO NV3YUY42TnWwY4Tpc44h[XO|YYm= MWixNlAhdWmwcx?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6geZB1[WunIH;mJHsyPEOfQV3HJIFnfGW{IEGyNEBucW6|IHL5JHRweEOxdX70JI1mfGixZDygTWM2OCB;IECuOlI6KM7:TT6= NWHWN|d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OFc4QTFpPkK4OFQ4PzlzPD;hQi=>
CHO M{LiOGZ2dmO2aX;uJIF{e2G7 M3\3RlEhcHJ? NG[yPZZKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFtzNFPdRW1IKHWydHHr[UBi\nSncjCxJIhzKGK7IH3pZ5Jw[mW2YTDjc5VvfGmwZzDt[ZRpd2RuIFXDOVAhRSByLkCwNkDPxE1w NXe0RohHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNVY2PjBpPkK5NlE3PTZyPD;hQi=>
CHO NETGS3JHfW6ldHnvckBie3OjeR?= M3y4O|EhcHJ? M2CyVmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzF2Q23BUWchfXC2YXvlJIFnfGW{IEGgbJIh[nlibXnjdo9j\XSjIHPveY51cW6pIH3leIhw\CxiRVO1NEA:KDBwOE[g{txONg>? MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MU[1OlAoRjJ7MkG2OVYxRC:jPh?=
CHO M4H5fGZ2dmO2aX;uJIF{e2G7 MVKxJIhz MYrJcohq[mm2aX;uJI9nKG[3bHytcIVv\3SqIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hYzF2Q22tcYV1cHmuIHHsdIhiNURvZ3z1Z49xgXKjbn;zbYRmKHWydHHr[UBi\nSncjCxJIhzKGK7IHzpdZVq\CC|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNFAyODVizszNMi=> M2TxRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{[0O|QzLz5{OUe2OFc1OjxxYU6=
HEK293 MVjGeY5kfGmxbjDhd5NigQ>? NWr1PVV1OTBibXnudy=> MXnJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hYzF2Q22tRW1IKHWydHHr[UBxemWrbnP1ZoF1\WRiZn;yJFExKG2rboOg[o9tdG:5ZXSgZpkhYzF2Q22tRW1IKGGmZHn0bY9vKGGwZDDt[YF{fXKnZDDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkCwNVQh|ryPLh?= M{DSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUW0OlgzLz5{OUm1OFY5OjxxYU6=
HEK293 MnTnSpVv[3Srb36gZZN{[Xl? MVmxNEBucW6| NIm4UVZKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iW{G0R30uSU2JIIXweIFs\SCycnXpcoN2[mG2ZXSg[o9zKDFyIH3pcpMh\m:ubH;3[YQh[nliW{G0R30uSU2JIHHk[Il1cW:wIHHu[EBu\WG|dYLl[EBi\nSncjCyJIhzeyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{Bu\XSqb3SsJGlEPTBiPTCxMlg{KM7:TT6= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl3NE[4Nkc,Ojl7NUS2PFI9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
HIF-1α / p-AMPK / AMPK / p-ERK / ERK / β-actin; 

PubMed: 27391020     


Effects of dapagliflozin on HIF1 in HK2 cells. (A) Representative Western blot: dapagliflozin increased HIF1 expression and phosphorylation of AMPK and ERK in hypoxic HK2 cells. *P < 0.05 vs., dapagliflozin nontreated normoxic HK2 cells, #P < 0.05 vs. normoxic HK2 cells. **P < 0.05 vs. control hypoxic HK2 cells.

DDR1; 

PubMed: 31979355     


(a) Effect of dapagliflozin on DDR1 (N-terminus antibody). HCT116 cells were treated with either vehicle (−; lane 2) or 0.5 mM dapagliflozin (+; lane 1) for 20 min. Cell extracts were prepared and immunoblotted with an amino-terminal anti-DDR1 antibody. Only full length-DDR1 was detected. The quantification of the DRR1 protein is presented as a bar graph (n = 3, * p < 0.001). The closed column represents cells treated with 0.5 mM dapagliflozin and the open column represents DMSO-treated cells.

HIF-1α / PHD2 / tubulin; 

PubMed: 32444604     


K. Western blot analysis of HIF-1α and PHD2 protein and relative protein expression level in the groups as indicated.

p-elf2α / t-elf2α / tubulin-α; 

PubMed: 31285506     


Dapagliflozin regulates unfolded protein response through the eIF2α pathway in HK-2 cells. (a) HK2 cells were treated with 2 μM dapagliflozin for 36 h with varying concentrations of D-galactose. Immunoblotting was performed with the indicated antibodies. (b) HK2 cells were transfected by siRNA for elf2α and incubated with 2 μM dapagliflozin for 36 h. Immunoblotting was performed with the indicated antibodies.

Bax / Bcl2 / PARP / β-actin; 

PubMed: 27391020     


(A) Western blot analysis shows dapagliflozin decreased Bax expression and increased Bcl2 expression in IR-injured kidneys. Dapalgliflozin decreased PARP expression in IR-injured kidneys.

27391020 31979355 32444604 31285506
Growth inhibition assay
Tumor volume; 

PubMed: 28763435     


Effects of dapagliflozin on tumor growth in vivo and pathology changes in tumor tissue of nude mice induced by dapagliflozin. The stable expressing CaKi-1 cells were used for in vivo research. (A) Tumor bodies after being treated with saline or dapagliflozin for 21 days. (B) Tumor volume was calculated at 3, 7, 10, 14, and 21 days after injection.

28763435
IHC
TUNEL-positive cells; 

PubMed: 27391020     


(B) Representative kidney section. Dapagliflozin decreased the TUNEL-positive cells in an IR-injured kidney.

HIF1; 

PubMed: 27391020     


(B) Representative Immunohistochemistry of HIF1. Dapagliflozin increase the HIF1 stained area in tubular area of IR kidney. Original magnification, 200×

TUNEL-positive cells; 

PubMed: 27391020     


(D–F) Representative kidney section: albendazole treatment increase tubulointerstitial injury and TUNEL-positive cells in IR-injured kidneys. *P < 0.05 vs. vehicle-treated sham, **P < 0.05 vs. vehicle-treated IR, #P < 0.05 vs. dapagliflozin-treated IR. Bar represents mean ± s.d.

mice kidney sections; 

PubMed: 32444604     


Administration of dapagliflozin ameliorates glomerular and tubular damage of diabetic kidney. H. Representative images of mice kidney sections from the groups indicated with H&E, PAS, Masson, Sirius red staining, and immunostaining for F4/80. Scale bar = 50 μm.

HE staining / SGLT2; 

PubMed: 28763435     


Effects of dapagliflozin on tumor growth in vivo and pathology changes in tumor tissue of nude mice induced by dapagliflozin. The stable expressing CaKi-1 cells were used for in vivo research. (G) HE staining and (H) SGLT2 immunohistochemistry staining from nude mice after being treated with saline or dapagliflozin for 21 days. Original magnification: 400×.

27391020 32444604 28763435
Immunofluorescence
Metabolic switch in diabetic kidneys; 

PubMed: 32444604     


Metabolic switch in diabetic kidneys is attenuated by dapagliflozin treatment. A. Representative images of mice kidney sections from the groups with BODIPY staining. Scale bars, 25 μm.

F-actin; 

PubMed: 32848736     


Dapagliflozin enhances skeletal muscle cells’ migration potential under hyperglycemia. (E, F) Polymerization of F-actin in C2C12 cells treated with dapagliflozin (final concentration: 10 μM), as analyzed using phalloidin staining: (E) representative images (scale bars: 100 μm for upper panels and 50 μm for lower panels) and (F) quantification of fractal dimension (n = 6) were shown. All experiments were done under hyperglycemic and hypoxic conditions. Cells treated with DMSO were used as controls.

EdU; 

PubMed: 32848736     


(C) The effect of dapagliflozin treatment (final concentration: 10 μM) on HIF-1α-silenced C2C12 cells’ proliferation potential as evaluated by EdU incorporation assay: representative images (scale bars: 100 μm) were shown.

PECAM-1 / α-SMA; 

PubMed: 32848736     


Dapagliflozin enhances neovascularization in diabetic HLI mice. Immunofluorescence against PECAM-1 (green) and α-SMA (red) in ischemic hindlimbs tissue of diabetic HLI mice administrated intramuscularly with dapagliflozin at day 21 after surgery: (A) representative images (scale bars: 100 μm) were shown.

podocytes; 

PubMed: 30089717     


Dapagliflozin limits podocyte depletion in mice with protein-overload proteinuria. Representative images and quantification of WT1-positive podocytes (red) expressed as number per glomerulus (A), podocyte density (B), and glomerular volume (C) in control mice (n = 6) and in BSA-mice treated with vehicle, dapagliflozin (DAPA), or ACE inhibitor (ACEi) (n = 8 each group), evaluated on day 23 after starting BSA. Scale bars: 20 μm. Data are the mean ± SEM and were analyzed by ANOVA with Tukey’s post hoc test.

32444604 32848736 30089717
In vivo Dapagliflozin reduces blood glucose levels by 55% after 0.1 mg/kg oral dose in hyperglycemic streptozotocin (STZ) rats, which is in part to the metabolic stability conferred by the C-glucoside linkage. Dapagliflozin displays a favorable absorption, distribution, metabolism, and excretion (ADME) profile and is orally bioavailable. [1] Dapagliflozin (1 mg/kg) causes significant dose-dependent glucosuria and increase in urine volume in normal rats over 24 hours post-dose. Dapagliflozin induces increase in urine glucose and urine volume excretion at 6 hours post-dose in Zucker diabetic fatty (ZDF) rats. Dapagliflozin lowers fasting and fed glucose levels in ZDF rats even by 2 weeks of treatment, without any marker of renal or liver toxicity. [2] Dapagliflozin significantly reduces the development of hyperglycaemia, with lowered blood glucose. Dapagliflozin could improve the insulin sensitivity, reduce β-cell mass and the development of impaired pancreatic function. [4]

Protocol

Animal Research:[1]
- Collapse
  • Animal Models: Normal Sprague Dawley rats or streptozotocin induced male Sprague Dawley rats
  • Dosages: 0.01-10 mg/kg (1 mL/kg) followed by a 50% glucose solution (2 g/kg)
  • Administration: Dosed orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.55 mM)
Water Insoluble
Ethanol ''17 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5% tween80+50% H2O
For best results, use promptly after mixing.
4.1 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.87
Formula

C21H25ClO6

CAS No. 461432-26-8
Storage powder
in solvent
Synonyms N/A
Smiles CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04887935 Not yet recruiting Drug: Dapagliflozin Prostate Cancer|Cancer of Prostate Washington University School of Medicine September 30 2022 Phase 1
NCT04923295 Recruiting Drug: Dapagliflozin 10Mg Tab Peritoneal Dialysis Complication|Ultrafiltration Failure An-Najah National University June 2 2021 Not Applicable
NCT05017987 Completed Drug: ATB-101 ATB-1011 ATB-1012 Healthy Adult Volunteers Autotelicbio June 19 2021 Phase 1
NCT04724837 Recruiting Drug: Zibotentan|Drug: Dapagliflozin|Drug: Placebo Chronic Kidney Disease AstraZeneca April 28 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

SGLT Signaling Pathway Map

Related SGLT Products

Tags: buy Dapagliflozin (BMS-512148) | Dapagliflozin (BMS-512148) supplier | purchase Dapagliflozin (BMS-512148) | Dapagliflozin (BMS-512148) cost | Dapagliflozin (BMS-512148) manufacturer | order Dapagliflozin (BMS-512148) | Dapagliflozin (BMS-512148) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID